OncoCompass™ Target Cancer Mutation Profiling Liquid Kit
Liquid biopsy for cancer patients
OncoCompass™ Target Cancer Mutation Profiling Liquid Kit is a CE-marked liquid biopsy test for cancer patients. It is a qualitative NGS-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of mutations in 101 genes in cell-free DNA extracted from plasma of peripheral whole blood in patients with solid malignant neoplasms. Mutations include single nucleotide mutation (SNV) and InDel in 99 genes, rearrangement (fusion) in 10 genes, and CNV in 13 genes, and MSI.
With a simple blood draw, the test analyzes guideline-recommended genes and guides treatment strategies for multiple cancer indications.